Rationale
Concern for drug-drug interactions leading to treatment failure and drug resistant strains have discouraged clinicians from attempting concomitant treatment of hepatitis C (HCV) and Tuberculosis. Increased metabolism of direct-acting antivirals (DAAs) by rifamycins has hindered concurrent use. Development of an assay for ledipasvir and sofosbuvir (LDV/SOF) serum concentrations for therapeutic drug monitoring (TDM) can ensure adequate therapy. Presented are the first cases of concomitant therapy of active TB and HCV with rifamycin containing regimens and DAAs using TDM.
Objectives
Using TDM, we aim to determine if concomitant therapy with rifamycin containing regimens and DAAs is safe and effective for patients co-infected with TB and HCV.
Methods
Five individuals with TB and HCV who experienced transaminitis prior to or during TB therapy, were concomitantly treated with rifamycin containing regimens and LDV/SOF. TDM was performed for ledipasvir, sofosbuvir and rifabutin during therapy. Baseline labs and serial liver enzymes were performed. HCV viral load and mycobacterial sputum cultures were obtained upon completion of therapy to determine efficacy of therapy.
Measurements and Main Results
All patients were found to have nondetectable HCV viral loads and negative mycobacterial sputum cultures upon completion of therapy. No clinically significant adverse effects were reported.
Conclusions
These cases illustrate concomitant use of LDV/SOF and rifabutin in patients with HCV/TB coinfection. Utilizing serum drug concentration monitoring to guide dosing, correction of transaminitis were achieved which allowed the use rifamycin containing TB therapy. These findings suggest that concomitant therapy of TB/HCV is possible, safe and effective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.